# Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial
Canonical URL: https://biopharmsignal.com/news/OCS/oculis-announces-agreement-with-fda-on-a-special-protocol-assessment-spa-for-optic-neuritis-registrational-trial
Ticker: OCS
Company: Oculis
Source: Oculis
Published: 2026-05-07 08:58 EST
Original Source URL: https://investors.oculis.com
## Summary

Special Protocol Assessment (SPA) agreement with the U.S. FDA provides regulatory alignment on the registrational path for Privosegtor in optic neuritis (ON) FDA Breakthrough Therapy and EMA PRIME designations in ON underscore the significant unmet need and therapeutic potential of Privosegtor as a

## Article Body
Special Protocol Assessment (SPA) agreement with the U.S. FDA provides regulatory alignment on the registrational path for Privosegtor in optic neuritis (ON) FDA Breakthrough Therapy and EMA PRIME designations in ON underscore the significant unmet need and therapeutic potential of Privosegtor as a
## Recent Company News
- 2026-05-29 19:06 EST — [Oculis Announces Topline Results from DIAMOND Phase 3 Trials with OCS-01 in Diabetic Macular Edema](https://biopharmsignal.com/news/OCS/oculis-announces-topline-results-from-diamond-phase-3-trials-with-ocs-01-in-diabetic-macular-edema) — Source: Oculis
- 2026-05-14 20:05 EST — [Oculis Publishes Results of 2026 Annual General Meeting and Announces Election of Gregory D. Perry to its Board of Directors](https://biopharmsignal.com/news/OCS/oculis-publishes-results-of-2026-annual-general-meeting-and-announces-election-of-gregory-d-perry-to-its-board-of-directors) — Source: Oculis
- 2026-05-11 20:07 EST — [Oculis Reports Q1 2026 Financial Results and Provides Company Update](https://biopharmsignal.com/news/OCS/oculis-reports-q1-2026-financial-results-and-provides-company-update) — Source: Oculis
- 2026-05-07 08:58 EST — [Oculis Announces Agreement with FDA on a Special Protocol Assessment (SPA) for Optic Neuritis Registrational Trial](https://biopharmsignal.com/news/OCS/oculis-announces-agreement-with-fda-on-a-special-protocol-assessment-spa-for-optic-neuritis-registrational-trial) — Source: Oculis
- 2026-05-05 08:00 EST — [Latest Findings from DME AWARE Delphi Study Presented at ARVO 2026 Annual Meeting](https://biopharmsignal.com/news/OCS/latest-findings-from-dme-aware-delphi-study-presented-at-arvo-2026-annual-meeting) — Source: Oculis
## Related News
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)
- 2026-07-21 11:30 EST — ABEO — [Cincinnati Children's Activated as the Seventh Qualified Treatment Center for ZEVASKYN®](https://biopharmsignal.com/news/ABEO/cincinnati-children-s-activated-as-the-seventh-qualified-treatment-center-for-ze-8382d043)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)